Institution
University of Cologne
Education•Cologne, Germany•
About: University of Cologne is a education organization based out in Cologne, Germany. It is known for research contribution in the topics: Population & Gene. The organization has 32050 authors who have published 66350 publications receiving 2210092 citations. The organization is also known as: Universität zu Köln & Universitatis Coloniensis.
Topics: Population, Gene, Transplantation, Medicine, Cancer
Papers published on a yearly basis
Papers
More filters
••
University of Cologne1, University of Freiburg2, Fred Hutchinson Cancer Research Center3, University of Regensburg4, University of Liverpool5, Lund University6, University of Basel7, Discovery Institute8, Imperial College London9, Northwestern University10, National Institutes of Health11, Stanford University12, University of Manchester13, French Institute of Health and Medical Research14, Washington University in St. Louis15, Yokohama City University16, Karolinska Institutet17, Vanderbilt University18, Harvard University19, Max Planck Society20, Osaka University21, University of Copenhagen22, Thomas Jefferson University23, University of Helsinki24, University of Erlangen-Nuremberg25, Rutgers University26
TL;DR: A new identification system for a trimer using three Arabic numerals, based on the alpha, beta and gamma chain numbers is introduced, which is introduced for laminin trimers.
836 citations
••
University of Cologne1, University of Zurich2, Cornell University3, University of Bonn4, Max Planck Society5, Peter MacCallum Cancer Centre6, St. Vincent's Health System7, Joseph Fourier University8, Oslo University Hospital9, Schiller International University10, University of Groningen11, VU University Medical Center12, Vanderbilt University13
TL;DR: F focal FGFR1 amplification is common in squamous cell lung cancer and associated with tumor growth and survival, suggesting that FGFR inhibitors may be a viable therapeutic option in this cohort of patients.
Abstract: Lung cancer remains one of the leading causes of cancer-related death in developed countries. Although lung adenocarcinomas with EGFR mutations or EML4-ALK fusions respond to treatment by epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) inhibition, respectively, squamous cell lung cancer currently lacks therapeutically exploitable genetic alterations. We conducted a systematic search in a set of 232 lung cancer specimens for genetic alterations that were therapeutically amenable and then performed high-resolution gene copy number analyses. We identified frequent and focal fibroblast growth factor receptor 1 (FGFR1) amplification in squamous cell lung cancer (n = 155), but not in other lung cancer subtypes, and, by fluorescence in situ hybridization, confirmed the presence of FGFR1 amplifications in an independent cohort of squamous cell lung cancer samples (22% of cases). Using cell-based screening with the FGFR inhibitor PD173074 in a large (n = 83) panel of lung cancer cell lines, we demonstrated that this compound inhibited growth and induced apoptosis specifically in those lung cancer cells carrying amplified FGFR1. We validated the FGFR1 dependence of FGFR1-amplified cell lines by FGFR1 knockdown and by ectopic expression of an FGFR1-resistant allele (FGFR1(V561M)), which rescued FGFR1-amplified cells from PD173074-mediated cytotoxicity. Finally, we showed that inhibition of FGFR1 with a small molecule led to significant tumor shrinkage in vivo. Thus, focal FGFR1 amplification is common in squamous cell lung cancer and associated with tumor growth and survival, suggesting that FGFR inhibitors may be a viable therapeutic option in this cohort of patients.
828 citations
••
TL;DR: Hakai as mentioned in this paper is an E3 ubiquitin-ligase that interacts with E-cadherin in a tyrosine phosphorylation-dependent manner, inducing ubiquitination of the Ecadin complex.
Abstract: In epithelial cells, tyrosine kinases induce the tyrosine phosphorylation and ubiquitination of the E-cadherin complex, which induces endocytosis of E-cadherin. With a modified yeast 2-hybrid system, we isolated Hakai, an E-cadherin binding protein, which we have identified as an E3 ubiquitin-ligase. Hakai contains SH2, RING, zinc-finger and proline-rich domains, and interacts with E-cadherin in a tyrosine phosphorylation-dependent manner, inducing ubiquitination of the E-cadherin complex. Expression of Hakai in epithelial cells disrupts cell--cell contacts and enhances endocytosis of E-cadherin and cell motility. Through dynamic recycling of E-cadherin, Hakai can thus modulate cell adhesion, and could participate in the regulation of epithelial--mesenchymal transitions in development or metastasis.
825 citations
••
TL;DR: In this article, Hall effect measurements were used to establish quantitatively the predicted emergent electrodynamics of skyrmions in chiral magnets and their depinning from impurities and their subsequent motion.
Abstract: When an electron moves in a smoothly varying non-collinear magnetic structure, its spin orientation adapts constantly, thereby inducing forces that act both on the magnetic structure and on the electron. These forces may be described by electric and magnetic fields of an emergent electrodynamics1, 2, 3, 4. The topologically quantized winding number of so-called skyrmions—a type of magnetic whirl discovered recently in chiral magnets5, 6, 7—has been predicted to induce exactly one quantum of emergent magnetic flux per skyrmion. A moving skyrmion is therefore expected to induce an emergent electric field following Faraday’s law of induction, which inherits this topological quantization8. Here we report Hall-effect measurements that establish quantitatively the predicted emergent electrodynamics. We obtain quantitative evidence for the depinning of skyrmions from impurities (at current densities of only 106 A m−2) and their subsequent motion. The combination of exceptionally small current densities and simple transport measurements offers fundamental insights into the connection between the emergent and real electrodynamics of skyrmions in chiral magnets, and might, in the long term, be important for applications.
823 citations
••
Paris 12 Val de Marne University1, University Medical Center Groningen2, Eindhoven University of Technology3, University Hospital of Lausanne4, French Institute of Health and Medical Research5, Università Campus Bio-Medico6, University of Belgrade7, University of Cologne8, Ludwig Maximilian University of Munich9, École Polytechnique Fédérale de Lausanne10, Turku University Hospital11, University of Regensburg12, Università telematica San Raffaele13, Paris Descartes University14, Paracelsus Private Medical University of Salzburg15, University of Bern16, Universidade Nova de Lisboa17, Medical Park18, University of Göttingen19, University of Messina20, Central European Institute of Technology21, University of Siena22, University of Turku23, University of Tübingen24
TL;DR: These updated recommendations take into account all rTMS publications, including data prior to 2014, as well as currently reviewed literature until the end of 2018, and are based on the differences reached in therapeutic efficacy of real vs. sham rT MS protocols.
822 citations
Authors
Showing all 32558 results
Name | H-index | Papers | Citations |
---|---|---|---|
Julie E. Buring | 186 | 950 | 132967 |
Stuart H. Orkin | 186 | 715 | 112182 |
Cornelia M. van Duijn | 183 | 1030 | 146009 |
Dorret I. Boomsma | 176 | 1507 | 136353 |
Frederick W. Alt | 171 | 577 | 95573 |
Donald E. Ingber | 164 | 610 | 100682 |
Klaus Müllen | 164 | 2125 | 140748 |
Klaus Rajewsky | 154 | 504 | 88793 |
Frederik Barkhof | 154 | 1449 | 104982 |
Stefanie Dimmeler | 147 | 574 | 81658 |
Detlef Weigel | 142 | 516 | 84670 |
Hidde L. Ploegh | 135 | 674 | 67437 |
Luca Valenziano | 130 | 437 | 94728 |
Peter Walter | 126 | 841 | 71580 |
Peter G. Martin | 125 | 553 | 97257 |